Caregivers’ preferences for the treatment of patients with Alzheimer’s disease
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To learn caregivers' preferences for the treatment of AD with a disease-slowing therapy, and to identify relationships between these preferences and the characteristics of caregivers and patients. METHODS: A structured interview with 40 caregivers of patients with AD. Preferences were measured for an AD-slowing medicine with the benefits of a gain in survival and a delay to nursing home placement (NHP), and risks of three degrees of severity of GI bleeding. RESULTS: Using a six-point scale ranging from "not at all important" to "extremely important," the median rating of the importance of survival as a treatment benefit was "very important" and of a delay to NHP was "extremely important." Fifty-five percent of the caregivers identified a benefit more important than these two benefits. Qualitative data showed that caregivers' reasons for these preferences featured the importance of patient quality of life, and the preservation of patient cognition and function. Bivariate analyses showed that increasing importance of the benefit of survival was related to higher assessments of the patient's health and quality of life, and lower ratings of the caregiver's experience of burden. In order to slow disease progression by 1 year, 25/38 (66%) of caregivers would accept some risk of death from gastrointestinal bleeding. Regression models showed that risk tolerance was higher among caregivers who were working, adult children caring for early stage patients or from families with an history of dementia. CONCLUSIONS: Caregivers generally are willing to tolerate notable amounts of risk to slow AD progression. Factors that describe the caregiver's experience and perception of the patient and the patient-caregiver relationship influence how they want to treat the disease. This information may be useful for decisions about how to study and prescribe AD treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Framing of Decisions and the Psychology of Choice
Tversky, A., & Kahneman, D. (1981) · Science · doi:10.1126/science.7455683 · Cited by 18,497
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Deciding for Others: The Ethics of Surrogate Decision Making
Buchanan, A. E., & Brock, D. W. (1990) · doi:10.1017/cbo9781139171946 · Cited by 516
Cited by
Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's Disease
Geldmacher, D. S., Provenzano, G., McRae, T., Mastey, V., & Ieni, J. R. (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1365-2389.2003.51306.x · Cited by 313
Caregiver Burden in Alzheimer Disease: Cross-Sectional and Longitudinal Patient Correlates
Mohamed, S., Rosenheck, R., Lyketsos, C. G., & Schneider, L. S. (2010) · The American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181d5745d · Cited by 292
Early identification and treatment of Alzheimer's disease: Social and fiscal outcomes
Weimer, D. L., & Sager, M. A. (2009) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2009.01.028 · Cited by 257
Deardorff, W. J., & Grossberg, G. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86463 · Cited by 125
“More definitive studies that demonstrate combination therapy delays admission to nursing homes would be important as delay in nursing home placement has been ranked by patients as an important metric in quality of life and would lower economic costs.(76) On an individual level, factors associated with a significantly…”
Reducing dangerous nighttime events in persons with dementia by using a nighttime monitoring system
Rowe, M. A., Kelly, A., Horne, C., Lane, S., Campbell, J., Lehman, B., Phipps, C., Keller, M., & Benito, A. P. (2009) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2008.08.005 · Cited by 72
“Although delaying nursing ome placement was rated as an extremely important issue or dementia caregivers [5], approximately 70% of caregivrs report the predominant reason they opt for nursing home lacement is the ongoing sleep disruption they suffer as a esult of PWDs’ erratic nighttime activity [6–8].”
Background
Metadata
- Authors
- Karlawish, J. H. T., Klocinski, J. L., Merz, J., Clark, C. M., & Asch, D. A.
- Venue
- Neurology
- Published
- 2000-10-10
- Volume
- 55
- Issue
- 7
- Pages
- 1008-1014
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2092448203
- Cited by
- 60
- References
- 3
- FWCI
- 3.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.